This year marks the 10-year anniversary of Eden Biodesign, so we thought it fitting to reflect on our past and look to the future as we remain committed to growth, success, and our long-standing reputation for being much more than a CMO. Eden has grown from a single- roomed office to a multinational organization with locations in the United States and Europe as well as partner organizations around the globe. We operate a custom-designed, 41,000 ft² MHRA-licensed multitechnology and multiproduct cGMP biomanufacturing center in Liverpool, UK, which now employs ~90 people and is poised for a new round of expansion.

In January 2010, Eden Biodesign was acquired, and it is now a wholly owned subsidiary of Watson Pharmaceuticals, Inc. (NYSE: WPI). Watson is a global specialty pharmaceutical company with £3 billion in revenues, a broad product line, and operations in well established and emerging markets. This provides Eden and our customers with extremely strong security as we continue to be dedicated to providing contract services to the marketplace.

Much More Than a CMO

Eden Biodesign maintains the entrepreneurial spirit, dedication to customer service, and unmatched knowledge of development of both biotherapeutic and vaccine products that served it so well in the early years. By “beginning with the end in mind” on every customer project, Eden Biodesign has developed a reputation for being “much more than a CMO” and successfully completed assignments for customers on six of the seven continents. We are a valued partner for organizations ranging from start-up biotechnology companies to multinational pharmaceutical companies and also serving governments, charities, and financial institutions along the way.We are unusual in that we offer process development and cGMP manufacturing services for products derived from all three major production platforms: mammalian, microbial, and viral. Thus, we have been able to assist customers in developing a wide range of different biological product types, including monoclonal antibodies, recombinant protein therapeutics, gene therapies, prophylactic, and therapeutic vaccines and cellular products.

We have direct experience in taking vaccines from concept to commercial licensure and expertise developed by working with a wide range of vaccine technologies. This know-how — coupled with our flexible, segregated, state-of-the-art facilities — makes us an ideal partner for vaccine developers. Over the past two years, we have invested considerable effort in building relationships with some of the leading technology developers, adding a range of technologies, methods, and procedures that can significantly benefit our clients through accelerated development programs and improved process economics. our powerful partnerships include BIA Separations, invitrogen PD Direct, Millipore, Oxford Expression Technologies, and Selexis.

Since opening the doors of our facility in 2006, we have completed well over eighty commercial projects, and our customer base continues to grow as our established track record and reputation attracts an increasing number of new partners and friends throughout the world. We do not develop any proprietary products; we develop and manufacture only for our clients. Although we provide access to the world’s leading production technologies, we do not seek royalty payments. Providing a development and manufacturing service to our clients receives our utmost attention and investment. With satisfied clients in Europe, North America, Asia, Africa, Australia, and Latin America, we provide a truly global service. To learn more about how we can assist your development programs and explore a new beginning, please contact us.

About the Author

Author Details
Roger Lias is president of Eden Biodesign, Inc. and group commercial director at 2530 Meridian Parkway, Suite 300, Durham, NC 27713;1-919-806-4949, 44-151-728-1750; [email protected]; www.edenbiodesign.com.